Article
Immunology
Astrid Z. Johansen, Sif I. Novitski, Jessica X. Hjaltelin, Susann Theile, Mogens K. Boisen, Soren Brunak, Daniel H. Madsen, Dorte L. Nielsen, Inna M. Chen
Summary: In this study, the association between plasma YKL-40 levels and clinical benefit and survival in patients with metastatic pancreatic cancer (mPC) receiving immune checkpoint inhibitors (ICIs) and stereotactic body radiotherapy (SBRT) was investigated. The results showed that elevated baseline plasma YKL-40 levels were associated with shorter overall survival, while a greater than 40% decrease in plasma YKL-40 levels during treatment was associated with longer progression-free survival and overall survival. These findings suggest that YKL-40 may serve as a potential biomarker for patients treated with immunotherapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Krzysztof Specjalski, Jan Romantowski, Marek Niedoszytko
Summary: Asthma is a chronic disorder characterized by inflammation and bronchial hyperresponsiveness. Chitinases and chitinase-like proteins (CLPs) have been suggested as potential biomarkers for diagnosing asthma and phenotyping the disease. However, the low specificity of these biomarkers limits their practical application.
FRONTIERS IN MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Kalthoum Tizaoui, Jae Won Yang, Keum Hwa Lee, Ji Hong Kim, Minseok Kim, Sojung Yoon, Yeonwoo Jung, Joon Beom Park, Kitae An, Hyeok Choi, Donggyu Song, HyunTaek Jung, Seongmin Ahn, Taeho Yuh, Hee Min Choi, Jae Ha Ahn, Younjuong Kim, Sanghyun Jee, Hyeongsun Lee, Soohwa Jun, Jun-Gu Kang, Bohyun Koo, Joo Yeop Lee, Kyoung Min Min, Wonseok Yoo, Hyeong Jun Rhyu, Yeonjung Yoon, Min Ho Lee, Sung Eun Kim, Jimin Hwang, Ai Koyanagi, Louis Jacob, Seoyeon Park, Jae Il Shin, Lee Smith
Summary: YKL-40, also known as CHI3L1 or HC gp-39, is a protein expressed by various cell types and speculated to be related to inflammatory reactions and autoimmune diseases. Studies have shown its potential as a marker for disease diagnosis, prognosis, disease activity, and treatment response, particularly in rheumatoid arthritis and psoriasis, but further research is needed to elucidate its exact role in autoimmunity.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Oncology
Kaisa Lehtomaki, Harri Mustonen, Pirkko-Liisa Kellokumpu-Lehtinen, Heikki Joensuu, Kethe Hermunen, Leena-Maija Soveri, Mogens Karsbol Boisen, Christian Dehlendorff, Julia Sidenius Johansen, Caj Haglund, Pia Osterlund
Summary: Colorectal cancer is the third most common cancer worldwide. Elevated post-adjuvant CEA, IL-6, and CRP are associated with impaired survival, and IL-6 can identify recurrences in patients with normal CEA. The lead time is shortest for CEA.
Article
Oncology
Il Hwan Oh, Jung-Soo Pyo, Byoung Kwan Son
Summary: This study found that YKL-40 expression in CRC tissues is associated with tumor differentiation and PD-L1 expression. The expression of I-YKL-40 can be useful for prognostic risk stratification in CRC patients.
Article
Clinical Neurology
Kevin Connolly, Mikael Lehoux, Ryan O'Rourke, Benedetta Assetta, Guzide Ayse Erdemir, Jack A. Elias, Chun Geun Lee, Yu-Wen Alvin Huang
Summary: CHI3L1 is a biomarker for early detection of neuroinflammation and disease diagnosis of AD. It is primarily provided by astrocytes in the brain and may play a crucial role in neuroinflammation and neurodegenerative diseases. In peripheral tissues, it is also a master regulator for injury and repair events.
ALZHEIMERS & DEMENTIA
(2023)
Review
Biotechnology & Applied Microbiology
Rongyan Qin, Ming Liao, Weili Qin, Jiawei Wang, Fengque Zheng, Nana Ma, Yunxiao Zhao, Aiping Qin
Summary: Serum YKL-40 is a potential biomarker for the early diagnosis of endometrial cancer (EC), and its combination with other biomarkers can improve diagnostic accuracy.
Article
Cell Biology
Guomei Shi, Minghao Li, E. Yan, Meng Wang, Pengyu Gong, Xiaorong Wang, Jingye Lu, Weixiang Wu, Shouru Xue, Junshan Zhou, Rujuan Zhou
Summary: The study aimed to investigate the association between serum YKL-40 levels at admission and one-year clinical outcomes in Chinese AIS patients. The findings suggested that elevated serum YKL-40 levels were independently associated with one-year poor outcome and all-cause mortality, but not stroke recurrence.
Article
Immunology
Guillaume Dorcet, Marie Benaiteau, Jeremie Pariente, Fabienne Ory-Magne, Emmanuel Cheuret, Marie Rafiq, Wesley Brooks, Benedicte Puissant-Lubrano, Francoise Fortenfant, Yves Renaudineau, Chloe Bost
Summary: This study aimed to explore the correlation between several biomarkers and the clinical course of autoimmune encephalitis (AIE). The results showed that the decrease in YKL-40 and MMP-9A at the protein level was associated with AIE remission, and the decrease in NfL and NfH levels in the serum was also associated with AIE remission. The study suggests that YKL-40 can be used as a biomarker to evaluate disease activity and therapeutic response in AIE.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2023)
Article
Oncology
Alex N. Videmark, Ib J. Christensen, Claus L. Feltoft, Mette Villadsen, Frederikke H. Borg, Barbara M. Jorgensen, Stig E. Bojesen, Caroline Kistorp, Randi Ugleholdt, Julia S. Johansen
Summary: This study investigated the diagnostic value of plasma CRP, IL-6, and YKL-40 in patients with nonspecific signs and symptoms of cancer. The results showed that elevated levels of these markers were associated with the risk of cancer, but they cannot be used to identify cancer patients. However, high levels were correlated with poor prognosis.
Review
Medical Laboratory Technology
Beibei Cui, Yuehong Chen, Fengming Luo, Sang Lin, Huan Liu, Yupeng Huang, Yueyuan Zhou, Yunru Tian, Geng Yin, Qibing Xie
Summary: This study investigated the clinical value of YKL-40 in patients with dermatomyositis (DM) through a cross-sectional study and a systematic review. The results of the cross-sectional study showed that serum YKL-40 levels were associated with the clinical course of DM and various laboratory parameters. The systematic review suggested that serum YKL-40 levels have the potential to diagnose PM/DM, identify patients with interstitial lung disease (ILD) or rapid progression ILD, and predict mortality.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Review
Medicine, General & Internal
Xiang Tong, Yao Ma, Tao Liu, Zhenzhen Li, Sitong Liu, Guihui Wu, Hong Fan
Summary: YKL-40 may be a useful biomarker for the diagnosis and prognosis of ILD, with varying levels in different types of ILD patients, correlation with lung function, and potential for survival prediction.
Article
Immunology
Sebastian Majewski, Karolina Szewczyk, Hanna Jerczynska, Joanna Milkowska-Dymanowska, Adam J. Bialas, Lukasz Gwadera, Wojciech J. Piotrowski
Summary: Elevated baseline serum CHIT1 activity and YKL-40 concentrations were found in IPF patients compared to control subjects. The study showed that longitudinal stable serum CHIT1 and YKL-40 levels may be associated with antifibrotic treatment response in IPF, with CHIT1 and YKL-40 potentially serving as diagnostic and prognostic biomarkers. Further research is needed to validate these findings.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Shuna Liu, Ming Wu, Fang Wang
Summary: Ovarian cancer presents a serious threat to women's health due to its low early diagnosis rate and tendency for metastasis and recurrence. Conventional treatment involving platinum and paclitaxel chemotherapy based on surgery may not effectively address the recurrence and progression of the disease. By understanding the molecular pathways involved in ovarian cancer recurrence and progression, biomarker-guided treatment options have the potential to significantly improve patient prognosis and lead to personalized treatment strategies.
Article
Medicine, General & Internal
Ioannis Mavroudis, Rumana Chowdhury, Foivos Petridis, Eleni Karantali, Symela Chatzikonstantinou, Ioana Miruna Balmus, Iuliana Simona Luca, Alin Ciobica, Dimitrios Kazis
Summary: Alzheimer's disease is a neurodegenerative disorder associated with inflammation. Elevated YKL-40 levels in the cerebrospinal fluid may serve as a biomarker for the diagnosis and management of AD.
MEDICINA-LITHUANIA
(2022)
Article
Multidisciplinary Sciences
Melissa Vos, Ruben Boers, Anne L. M. Vriends, Joachim Boers, Patricia F. van Kuijk, Winan J. van Houdt, Geert J. L. H. van Leenders, Michal Wagrodzki, Wilfred F. J. van IJcken, Joost Gribnau, Dirk J. Grunhagen, Cornelis Verhoef, Stefan Sleijfer, Erik A. C. Wiemer
Article
Multidisciplinary Sciences
Amanda Khoury, Joanna Achinger-Kawecka, Saul A. Bert, Grady C. Smith, Hugh J. French, Phuc-Loi Luu, Timothy J. Peters, Qian Du, Aled J. Parry, Fatima Valdes-Mora, Phillippa C. Taberlay, Clare Stirzaker, Aaron L. Statham, Susan J. Clark
NATURE COMMUNICATIONS
(2020)
Article
Multidisciplinary Sciences
Joanna Achinger-Kawecka, Fatima Valdes-Mora, Phuc-Loi Luu, Katherine A. Giles, C. Elizabeth Caldon, Wenjia Qu, Shalima Nair, Sebastian Soto, Warwick J. Locke, Nicole S. Yeo-Teh, Cathryn M. Gould, Qian Du, Grady C. Smith, Irene R. Ramos, Kristine F. Fernandez, Dave S. Hoon, Julia M. W. Gee, Clare Stirzaker, Susan J. Clark
NATURE COMMUNICATIONS
(2020)
Article
Pathology
Natalia Rusetska, Kamil Kowalski, Kamil Zalewski, Sebastian Zieba, Mariusz Bidzinski, Krzysztof Goryca, Beata Kotowicz, Malgorzata Fuksiewicz, Janusz Kopczynski, Elwira Bakula-Zalewska, Artur Kowalik, Magdalena Kowalewska
Summary: The study found that the CXCR4/ACKR3/CXCL12 axis is activated during progression and lymphatic spread of VSCC. CXCR4 and ACKR3 proteins are nearly absent in precancerous lesions but are strong in VSCC samples. Additionally, serum CXCL12 levels are significantly increased in both patients with VSCC and premalignant vulvar lesions.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Article
Oncology
Katherine A. Giles, Cathryn M. Gould, Joanna Achinger-Kawecka, Scott G. Page, Georgia R. Kafer, Samuel Rogers, Phuc-Loi Luu, Anthony J. Cesare, Susan J. Clark, Phillippa C. Taberlay
Summary: The study found that BRG1 is overexpressed in prostate cancer and mainly affects global transcription programs by down-regulating gene expression, with most downregulated genes related to proliferation. Depletion of BRG1 results in G1 arrest.
CLINICAL EPIGENETICS
(2021)
Article
Medicine, General & Internal
Aleksandra Sobiborowicz, Tomasz Switaj, Pawel Teterycz, Mateusz J. Spalek, Anna Szumera-Cieckiewicz, Michal Wagrodzki, Marcin Zdzienicki, Anna M. Czarnecka, Piotr Rutkowski
Summary: PEComas are a rare family of mesenchymal tumors, some of which are malignant. Patients treated surgically in national sarcoma centers have better disease control and survival rates. Microscopically radical resection is associated with longer disease-free survival.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Mateusz Jacek Spalek, Aneta Maria Borkowska, Maria Telejko, Michal Wagrodzki, Daria Niebylowska, Aldona Uzar, Magdalena Bialobrzeska, Piotr Rutkowski
Summary: For patients with marginally resectable or unresectable soft tissue sarcomas who are not candidates for chemotherapy, hypofractionated radiotherapy combined with hyperthermia is a feasible treatment option, demonstrating good short-term local efficacy and tolerance. This combination therapy may warrant further studies in soft tissue sarcomas.
Article
Cell Biology
Qian Du, Grady C. Smith, Phuc Loi Luu, James M. Ferguson, Nicola J. Armstrong, C. Elizabeth Caldon, Elyssa M. Campbell, Shalima S. Nair, Elena Zotenko, Cathryn M. Gould, Michael Buckley, Kee-Ming Chia, Neil Portman, Elgene Lim, Dominik Kaczorowski, Chia-Ling Chan, Kirston Barton, Ira W. Deveson, Martin A. Smith, Joseph E. Powell, Ksenia Skvortsova, Clare Stirzaker, Joanna Achinger-Kawecka, Susan J. Clark
Summary: This study reveals the association between genome-wide methylation loss, loss of replication timing precision, and deregulation of 3D genome organization. In cancer hypomethylation models, disruptions in 3D genome compartmentalization, increased cell-to-cell replication timing heterogeneity, and loss of allelic replication timing were observed.
Article
Medicine, General & Internal
Tomasz Switaj, Aleksandra Sobiborowicz, Pawel Teterycz, Anna Klimczak, Donata Makula, Michal Wagrodzki, Anna Szumera-Cieckiewicz, Piotr Rutkowski, Anna M. Czarnecka
Summary: The study demonstrates that sirolimus is an effective first-line treatment for PEComa patients, with a high objective response rate of 73% and disease control achieved in all patients. The 5-year overall survival rate was 65%, indicating promising long-term efficacy of targeted therapy for PEComa.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Hanna Kosela-Paterczyk, Pawel Teterycz, Mateusz J. Spalek, Aneta Borkowska, Anna Zawadzka, Michal Wagrodzki, Anna Szumera-Cieckiewicz, Tadeusz Morysinski, Tomasz Switaj, Iwona Lugowska, Patrycja Castaneda-Wysocka, Marcin Zdzienicki, Tomasz Goryn, Piotr Rutkowski
Summary: The study demonstrates that hypofractionated preoperative radiotherapy is associated with good local control and tolerance in patients with extensive, high-grade soft tissue sarcomas. Both early and late complications were minimal, indicating the effectiveness and safety of this treatment approach.
Review
Oncology
Lauren Julia Brown, Joanna Achinger-Kawecka, Neil Portman, Susan Clark, Clare Stirzaker, Elgene Lim
Summary: Epigenetic therapies are promising but not widely used in the management of breast cancer. The most studied treatments target DNA methylation and histone modification, but none have been approved for routine clinical use. Combination therapies may be more effective in breast cancer treatment. With advancing technology, more potential epigenetic biomarkers for treatment response are being identified.
Article
Multidisciplinary Sciences
Jordan F. Hastings, Sharissa L. Latham, Alvin Kamili, Madeleine S. Wheatley, Jeremy Z. R. Han, Marie Wong-Erasmus, Monica Phimmachanh, Max Nobis, Chiara Pantarelli, Antonia L. Cadell, Yolande E. I. O'Donnell, King Ho Leong, Sophie Lynn, Fan-Suo Geng, Lujing Cui, Sabrina Yan, Joanna Achinger-Kawecka, Clare Stirzaker, Murray D. Norris, Michelle Haber, Toby N. Trahair, Frank Speleman, Katleen De Preter, Mark J. Cowley, Ozren Bogdanovic, Paul Timpson, Thomas R. Cox, Walter Kolch, Jamie I. Fletcher, Dirk Fey, David R. Croucher
Summary: Gene expression noise promotes stochastic drug resistance in rare cancer cells. However, when integrated across multiple components of an apoptotic signaling network, the influence of noise leads to a higher frequency of chemoresistant neuroblastoma cells. These cells are characterized by JNK impairment and retain a memory of their resistant state even after chemotherapy treatment.
Meeting Abstract
Oncology
Hanna Kosela, Mateusz Spalek, Aneta Borkowska, Pawel Teterycz, Tadeusz Morysinski, Michal Wagrodzki, Tomasz Goryn, Marcin Zdzienicki, Piotr Rutkowski
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Meeting Abstract
Oncology
Beata Kotowicz, Pawel Winter, Malgorzata Fuksiewicz, Agnieszka Jagiello-Gruszfeld, Katarzyna Pogoda, Zbigniew Nowecki, Maria Kowalska
JOURNAL OF CLINICAL ONCOLOGY
(2020)